-
Something wrong with this record ?
Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature
J. Hrudka, K. Lawrie, P. Waldauf, V. Ciprová, J. Moravcová, R. Matěj,
Language English Country Germany
Document type Comparative Study, Journal Article, Review
Grant support
VFN64165
Ministerstvo Zdravotnictví Ceské Republiky
TN64190
Ministerstvo Zdravotnictví Ceské Republiky
Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509
Ministerstvo Zdravotnictví Ceské Republiky
PROGRES Q28 Oncology
Univerzita Karlova v Praze
NLK
ProQuest Central
from 2003-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2003-01-01 to 1 year ago
- MeSH
- B7-H1 Antigen analysis MeSH
- Cell Differentiation * MeSH
- Adult MeSH
- Carcinoma, Pancreatic Ductal immunology mortality pathology therapy MeSH
- Immunohistochemistry MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor analysis MeSH
- Pancreatic Neoplasms immunology mortality pathology therapy MeSH
- Giant Cells immunology pathology MeSH
- Osteoclasts immunology pathology MeSH
- Predictive Value of Tests MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Lymphocytes, Tumor-Infiltrating immunology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Comparative Study MeSH
Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027707
- 003
- CZ-PrNML
- 005
- 20210114152241.0
- 007
- ta
- 008
- 210105s2020 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-020-02830-8 $2 doi
- 035 __
- $a (PubMed)32424767
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hrudka, Jan $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. jan.hrudka@lf3.cuni.cz.
- 245 10
- $a Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature / $c J. Hrudka, K. Lawrie, P. Waldauf, V. Ciprová, J. Moravcová, R. Matěj,
- 520 9_
- $a Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antigeny CD274 $x analýza $7 D060890
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a duktální karcinom slinivky břišní $x imunologie $x mortalita $x patologie $x terapie $7 D021441
- 650 12
- $a buněčná diferenciace $7 D002454
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a obrovské buňky $x imunologie $x patologie $7 D015726
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a tumor infiltrující lymfocyty $x imunologie $7 D016246
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a osteoklasty $x imunologie $x patologie $7 D010010
- 650 _2
- $a nádory slinivky břišní $x imunologie $x mortalita $x patologie $x terapie $7 D010190
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Lawrie, Kateřina $u Department of General Surgery, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Waldauf, Petr $u Department of Anesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
- 700 1_
- $a Ciprová, Vanda $u Institute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Moravcová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Matěj, Radoslav $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. Institute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00004660 $t Virchows Archiv : an international journal of pathology $x 1432-2307 $g Roč. 477, č. 5 (2020), s. 687-696
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32424767 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152239 $b ABA008
- 999 __
- $a ok $b bmc $g 1608042 $s 1118887
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 477 $c 5 $d 687-696 $e 20200518 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- GRA __
- $a VFN64165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a TN64190 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a PROGRES Q28 Oncology $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20210105
